Roche News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

12.01.21	Roche confirms US government agreement to purchase additional doses of Regeneron’s casirivimab and imdevimab (GlobeNewswire)
12.01.21	Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer (GlobeNewswire)
11.01.21	Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer (GlobeNewswire)
11.01.21	Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years (GlobeNewswire)
05.01.21	Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer (GlobeNewswire)
23.12.20	European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer (GlobeNewswire)
21.12.20	Roche’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness (GlobeNewswire)
15.12.20	Roche launches cobas PIK3CA Mutation Test for patients with advanced or metastatic breast cancer in countries accepting the CE mark (GlobeNewswire)
14.12.20	FDA approves Roche’s OCREVUS® (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive multiple sclerosis (GlobeNewswire)
11.12.20	Roche launches laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients (GlobeNewswire)
10.12.20	Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020 (GlobeNewswire)
09.12.20	Roche partners with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials (GlobeNewswire)
08.12.20	Roche presents new data from its bispecific antibody portfolio across a range of blood cancers (GlobeNewswire)
07.12.20	New data presented at ASH 2020 reinforces the benefit/risk profile of fixed-duration Polivy plus bendamustine and MabThera/Rituxan in patients with relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
07.12.20	New follow-up phase III data reinforce the long-term benefit of Roche’s Hemlibra for people with haemophilia A (GlobeNewswire)
05.12.20	Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic lymphocytic leukaemia (GlobeNewswire)
02.12.20	Roche announces FDA approval of Gavreto (pralsetinib) for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers (GlobeNewswire)
02.12.20	Roche receives FDA Emergency Use Authorization for new test to measure the level of SARS-CoV-2 antibodies (GlobeNewswire)
01.12.20	FDA approves Xolair® (omalizumab) for adults with nasal polyps (GlobeNewswire)
24.11.20	Roche announces FDA approval of Xofluza for the prevention of influenza following contact with an infected person (GlobeNewswire)
16.11.20	Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the eleventh time (GlobeNewswire)
16.11.20	Roche zum elften Mal als nachhaltigstes Gesundheitsunternehmen im Dow Jones Sustainability Index ausgezeichnet (GlobeNewswire)
13.11.20	CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza (GlobeNewswire)
13.11.20	CHMP recommends EU approval of Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer (GlobeNewswire)
05.11.20	Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting (GlobeNewswire)
02.11.20	European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer (GlobeNewswire)
29.10.20	Roche’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer (GlobeNewswire)
22.10.20	Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients (GlobeNewswire)
19.10.20	Roche announces full FDA approval for Venclexta combinations for acute myeloid leukaemia (GlobeNewswire)
15.10.20	Wachstum von 1% zu konstanten Wechselkursen in den ersten neun Monaten, starker Einfluss der COVID-19-Pandemie (GlobeNewswire)
15.10.20	First nine months of the year with 1% sales growth at constant exchange rates, significant impact of COVID-19 pandemic (GlobeNewswire)
13.10.20	Roche to launch laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients (GlobeNewswire)
28.09.20	Roche presents new 2-year data for Evrysdi (risdiplam) in infants with Type 1 spinal muscular atrophy (SMA) (GlobeNewswire)
19.09.20	Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020 (GlobeNewswire)
18.09.20	Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer (GlobeNewswire)
18.09.20	Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines (GlobeNewswire)
18.09.20	Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia (GlobeNewswire)
17.09.20	Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020 (GlobeNewswire)
16.09.20	Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer (GlobeNewswire)
11.09.20	New data further reinforce Roche’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis (GlobeNewswire)
10.09.20	New data show Roche’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD) (GlobeNewswire)
09.09.20	Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab) (GlobeNewswire)
08.09.20	Roche receives FDA clearance for BK virus quantitative test on cobas 6800/8800 Systems to support better care for transplant patients (GlobeNewswire)
07.09.20	Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (GlobeNewswire)
04.09.20	Roche receives FDA Emergency Use Authorization for the cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems (GlobeNewswire)
03.09.20	Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020 (GlobeNewswire)
01.09.20	Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of care (GlobeNewswire)
01.09.20	Roche receives FDA approval for first HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the fight against HIV/AIDS (GlobeNewswire)
28.08.20	Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test (GlobeNewswire)
19.08.20	Roche and Regeneron collaborate to significantly increase global supply of REGN-COV2 investigational antibody combination for COVID-19 (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	297.00	1.43 %	K V
Lonza Grp	531.40	0.61 %	K V
ABB	49.00	0.55 %	K V
Givaudan	3’928.00	0.54 %	K V
Alcon	76.06	0.40 %	K V
Nestle	73.76	-0.59 %	K V
Holcim	86.46	-0.60 %	K V
Swisscom	498.40	-0.62 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Sika	213.70	-2.24 %	K V

mehr

15:58		Zurückhaltung in Europa: Euro STOXX 50 präsentiert sich schwächer
15:58		Börse Frankfurt: So steht der LUS-DAX am Nachmittag
15:58		Börse Frankfurt: DAX präsentiert sich nachmittags leichter
15:58		Anleger in London halten sich zurück: So bewegt sich der FTSE 100 aktuell
15:58		SPI-Handel aktuell: SPI verliert
15:58		Handel in Zürich: SMI verbucht Verluste
13:22		GSK-Aktie verliert: GSK erreicht Fortschritte bei Eierstockkrebs-Therapie
13:13		Wechsel bei Sanofi: Ex-Morphosys-Chef Kress tritt in den Verwaltungsrat ein -Sanofi-Aktie tiefer